Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study.

Autoantibodies Autoantigens Diabetes Mellitus, Type 2 Dipeptidyl-Peptidase IV Inhibitors / adverse effects Humans Immunoglobulin G Non-Fibrillar Collagens Pemphigoid, Bullous
BP180 autoantibody bullous pemphigoid epitope gliptin humoral response

Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
07 2022
Historique:
received: 15 10 2021
revised: 25 01 2022
accepted: 13 02 2022
pubmed: 4 3 2022
medline: 22 6 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

Recently, several case-control studies demonstrated an association between gliptins and bullous pemphigoid (BP) occurrence. However, data on the clinical and immunologic features of gliptin-associated bullous pemphigoid (GABP) are controversial. This study aimed to clinically and immunologically characterize a large cohort of GABP patients to get an insight into the pathophysiology of this emerging drug-induced variant of BP. Seventy-four GABP patients were prospectively enrolled and characterized from 9 different Italian dermatology units between 2013 and 2020. Our findings demonstrated the following in the GABP patients: (1) a noninflammatory phenotype, which is characterized by low amounts of circulating and skin-infiltrating eosinophils, is frequently found; (2) immunoglobulin (Ig)G, IgE, and IgA humoral responses to BP180 and BP230 antigens are reduced in frequency and titers compared with those in patients with idiopathic BP; (3) IgG reactivity targets multiple BP180 epitopes other than noncollagenous region 16A. A limitation of the study is that the control group did not comprise only type 2 diabetes mellitus patients with BP. GABP patients show peculiar features of anti-BP180 and -BP230 humoral responses, laying the foundation for diagnostic improvements and getting novel insights into understanding the mechanism of BP onset.

Sections du résumé

BACKGROUND
Recently, several case-control studies demonstrated an association between gliptins and bullous pemphigoid (BP) occurrence. However, data on the clinical and immunologic features of gliptin-associated bullous pemphigoid (GABP) are controversial.
OBJECTIVE
This study aimed to clinically and immunologically characterize a large cohort of GABP patients to get an insight into the pathophysiology of this emerging drug-induced variant of BP.
METHODS
Seventy-four GABP patients were prospectively enrolled and characterized from 9 different Italian dermatology units between 2013 and 2020.
RESULTS
Our findings demonstrated the following in the GABP patients: (1) a noninflammatory phenotype, which is characterized by low amounts of circulating and skin-infiltrating eosinophils, is frequently found; (2) immunoglobulin (Ig)G, IgE, and IgA humoral responses to BP180 and BP230 antigens are reduced in frequency and titers compared with those in patients with idiopathic BP; (3) IgG reactivity targets multiple BP180 epitopes other than noncollagenous region 16A.
LIMITATIONS
A limitation of the study is that the control group did not comprise only type 2 diabetes mellitus patients with BP.
CONCLUSION
GABP patients show peculiar features of anti-BP180 and -BP230 humoral responses, laying the foundation for diagnostic improvements and getting novel insights into understanding the mechanism of BP onset.

Identifiants

DOI: 10.1016/j.jaad.2022.02.036 PMID: 35240229
pubmed: 35240229
pii: S0190-9622(22)00350-4
doi: 10.1016/j.jaad.2022.02.036
pii:
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
Dipeptidyl-Peptidase IV Inhibitors 0
Immunoglobulin G 0
Non-Fibrillar Collagens 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-63

Informations de copyright

Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest None disclosed.

Auteurs

Adele Salemme (A)

Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy.

Luca Fania (L)

First Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Alessandra Scarabello (A)

Dermatology unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.

Marzia Caproni (M)

Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, Italy.

Angelo Valerio Marzano (AV)

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.

Emanuele Cozzani (E)

DiSSal, Dermatology Clinic, San Martino Polyclinic Hospital-IRCCS, University of Genoa, Genoa, Italy.

Claudio Feliciani (C)

Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Clara De Simone (C)

Institute of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università del Sacro Cuore, Rome, Italy.

Manuela Papini (M)

Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Rosanna Rita Satta (RR)

Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.

Aurora Parodi (A)

DiSSal, Dermatology Clinic, San Martino Polyclinic Hospital-IRCCS, University of Genoa, Genoa, Italy.

Feliciana Mariotti (F)

Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy.

Stefania Lechiancole (S)

First Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Giovanni Genovese (G)

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.

Francesca Passarelli (F)

Pathology Unit, IDI-IRCCS, Rome, Italy.

Francesca Festa (F)

First Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Barbara Bellei (B)

Laboratory of Cutaneous Physiopathology and Integrated Center for Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.

Alessia Provini (A)

First Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Donatella Sordi (D)

First Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Sabatino Pallotta (S)

Fifth Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Damiano Abeni (D)

Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.

Cinzia Mazzanti (C)

First Dermatology Clinic, IDI-IRCCS, Rome, Italy.

Biagio Didona (B)

Rare disease Unit, IDI-IRCCS, Rome, Italy.

Giovanni Di Zenzo (G)

Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy. Electronic address: g.dizenzo@idi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Autoantigènes › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs de la dipeptidyl-peptidase IV › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Scléroprotéines › Protéines de la matrice extracellulaire › Collagène › Collagènes non fibrillaires › Gliptin-associated bullous pemphigoid shows...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Pemphigoïde bulleuse › Gliptin-associated bullous pemphigoid shows...